ChiCTR2500109074 版本V1.0 版本创建时间2025/09/11 10:12:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500109074 

最近更新日期:

Date of Last Refreshed on:

2025-09-11 10:12:17 

注册时间:

Date of Registration:

2025-09-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

极早产儿/极低出生体重儿生存质量与健康结局的回顾性单中心队列研究及其相关因素分析

Public title:

A retrospective single-centre cohort study of quality of survival and health outcomes in very preterm/very low birth weight infants and analysis of its associated factors

注册题目简写:

English Acronym:

研究课题的正式科学名称:

极早产儿/极低出生体重儿生存质量与健康结局的回顾性单中心队列研究及其相关因素分析

Scientific title:

A retrospective single-centre cohort study of quality of survival and health outcomes in very preterm/very low birth weight infants and analysis of its associated factors

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

崔雪薇 

研究负责人:

石永言 

Applicant:

Cui Xuewei 

Study leader:

Shi Yongyan 

申请注册联系人电话:

Applicant telephone:

+86 189 4025 2472

研究负责人电话:

Study leader's telephone:

+86 189 4025 6916

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xwcui@cmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

yyshi@cmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

沈阳市和平区三好街36号

研究负责人通讯地址:

沈阳市和平区三好街36号

Applicant address:

No. 36 Sanhao Street, Heping District, Shenyang

Study leader's address:

No. 36 Sanhao Street, Heping District, Shenyang

申请注册联系人邮政编码:

Applicant postcode:

110004

研究负责人邮政编码:

Study leader's postcode:

110004

申请人所在单位:

中国医科大学附属盛京医院

Applicant's institution:

Shengjing Hospital of China Medical University

研究负责人所在单位:

中国医科大学附属盛京医院

Affiliation of the Leader:

Shengjing Hospital of China Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025PS1550K

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医科大学附属盛京医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shengjing Hospital of China Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-01 00:00:00

伦理委员会联系人:

金晶

Contact Name of the ethic committee:

Jin Jing

伦理委员会联系地址:

沈阳市和平区三好街36号

Contact Address of the ethic committee:

No. 36 Sanhao Street, Heping District, Shenyang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 24 966 151 0027

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医科大学附属盛京医院

Primary sponsor:

Shengjing Hospital of China Medical University

研究实施负责(组长)单位地址:

沈阳市和平区三好街36号

Primary sponsor's address:

No. 36 Sanhao Street, Heping District, Shenyang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

沈阳

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

中国医科大学附属盛京医院

具体地址:

沈阳市和平区三好街36号

Institution
hospital:

Shengjing Hospital of China Medical University

Address:

No. 36 Sanhao Street, Heping District, Shenyang

经费或物资来源:

国家自然科学基金(批准号:82171709,82301949)

Source(s) of funding:

National Natural Science Foundation of China (Grant No. 82171709,82301949)

Target disease:

Short-term and long-term complications in preterm infants

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

构建VPI/VLBWI多维生存质量评估体系,量化围产期特异性事件(如胎儿炎症反应综合征、绒毛膜羊膜炎、胎胎输血综合征、选择性宫内生长发育受限、sIUFD等)对存活儿预后的独立影响,探索胎盘病理特征与并发症的关联(如胎盘早剥→脑梗死),验证脐血生物标志物对早产儿并发症的预测价值,不断提高新生儿科以及相关支持学科技术水平和危急重症救治能力。  

Objectives of Study:

Establish a multidimensional quality of life assessment system for VPI/VLBWI infants, quantifying the independent impact of perinatal-specific events (such as foetal inflammatory response syndrome, chorioamnionitis, foetal-foetal transfusion syndrome, selective intrauterine growth restriction, sIUFD, etc.) on the prognosis of surviving infants. Investigate the association between placental pathological features and complications (e.g., placental abruption → cerebral infarction), validate the predictive value of umbilical cord blood biomarkers for preterm infant complications, and continuously enhance the technical proficiency and critical care capabilities of neonatal departments and related support disciplines.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

我院出生、胎龄<32周或体重<1500g的早产儿

Inclusion criteria

Inborn, gestational age <32 weeks or birth weight <1500 g

排除标准:

外院出生、非医嘱离院、重大先天畸形、临床资料不完整

Exclusion criteria:

Outborn, discharge against medical advice, major congenital malformations, incomplete clinical records

研究实施时间:

Study execute time:

From 2025-10-01 00:00:00 To 2031-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-10-01 00:00:00 To 2026-09-30 00:00:00  

干预措施:

Interventions:

组别:

暴露组

样本量:

1600

Group:

Exposed group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

6400

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

沈阳 

Country:

China 

Province:

Liaoning 

City:

Shenyang 

单位(医院):

中国医科大学附属盛京医院 

单位级别:

三甲 

Institution
hospital:

Shengjing Hospital, China Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

严重脑损伤

指标类型:

主要指标

Outcome:

Severe Brain Injury

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

支气管肺发育不良

指标类型:

主要指标

Outcome:

Bronchopulmonary dysplasia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿坏死性小肠结肠炎

指标类型:

主要指标

Outcome:

Neonatal necrotising enterocolitis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早产儿视网膜病

指标类型:

主要指标

Outcome:

retinopathy of prematurity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

有创通气时长

指标类型:

次要指标

Outcome:

Duration of invasive ventilation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时长

指标类型:

次要指标

Outcome:

Length of NICU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿呼吸窘迫综合征

指标类型:

次要指标

Outcome:

Neonatal respiratory distress syndrome

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动脉导管未闭

指标类型:

次要指标

Outcome:

Patent ductus arteriosus

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早发型脓毒症

指标类型:

次要指标

Outcome:

Early-onset sepsis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胎龄

指标类型:

附加指标

Outcome:

Gestational age

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

出生体重

指标类型:

附加指标

Outcome:

Birth weight

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

小于胎龄儿

指标类型:

附加指标

Outcome:

Small for gestational age infant

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

5分钟Apgar评分小于7分

指标类型:

附加指标

Outcome:

Apgar score <7 at 5 min

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

剖宫产

指标类型:

附加指标

Outcome:

Cesarean delivery

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产前糖皮质激素使用

指标类型:

附加指标

Outcome:

Antenatal steroids

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产前硫酸镁使用

指标类型:

附加指标

Outcome:

MgSO4

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

妊娠期糖尿病

指标类型:

附加指标

Outcome:

Gestational diabetes mellitus

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

妊娠期高血压

指标类型:

附加指标

Outcome:

Pregnancy-induced hypertension

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

辅助生殖

指标类型:

附加指标

Outcome:

Assisted reproduction

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

绒毛膜羊膜炎

指标类型:

附加指标

Outcome:

chorioamnionitis

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究为观察性队列研究,不涉及随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is an observational cohort study and does not involve randomised groups

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not applicable.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究的数据采集与管理流程如下: 1. 病例记录表 (Case Record Form, CRF): 本研究采用自行设计的标准化数据提取表作为电子病例记录表(e-CRF)。该表格基于研究方案和统计分析计划,明确了所有需要采集的变量及其定义(包括人口学特征、围产期信息、治疗过程、并发症及结局指标等)。数据采集员通过回顾性查阅医院电子病历系统(EMR),将所需信息填写至此标准化数据提取表中。 2. 数据采集和管理系统 (Electronic Data Capture, EDC): 本研究使用 Microsoft Excel (版本号:Microsoft WPS) 构建研究数据库并进行数据管理。具体流程与质控措施包括: ? 数据录入:由经过培训的一名研究员将标准化数据提取表(e-CRF)中的信息录入到初始Excel数据库。 ? 逻辑核查:利用Excel的数据有效性验证功能(如设置数值范围、下拉列表等)对关键变量进行初步控制,减少录入错误。 ? 重复数据核对:使用Excel的“删除重复项”和“条件格式”等功能对唯一标识符(如住院号)进行核查,确保无重复录入。 ? 数据清理:通过Excel的排序、筛选、公式计算等功能,对数据的完整性、一致性和合理性进行人工审查与核对。 ? 隐私保护:所有收集的数据均进行匿名化处理。Excel数据库文件进行加密密码保护,存储在机构指定的安全计算机中,仅研究团队成员有权访问。定期对数据库进行备份。 ? 数据审核:由第二人独立核对原始病历与Excel数据库中录入的数据的一致性,或对关键指标进行100%复核,以确保数据的准确性。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection and management process for this study is as follows: 1. Case Record Form (CRF): This study employs a custom-designed standardised data extraction form as the electronic case record form (e-CRF). Based on the study protocol and statistical analysis plan, this form specifies all required variables and their definitions (including demographic characteristics, perinatal information, treatment procedures, complications, and outcome measures). Data collectors retrospectively reviewed the hospital's electronic medical record (EMR) system and populated this standardised data extraction form with the required information. 2. Data Capture and Management System (Electronic Data Capture, EDC): Microsoft Excel (version: Microsoft WPS) was utilised to construct the study database and manage data. Specific procedures and quality control measures included: ? Data entry: A trained researcher entered information from the standardised data extraction form (e-CRF) into the initial Excel database. ? Logical verification: Preliminary control of key variables was achieved using Excel's data validation features (e.g., setting numerical ranges, dropdown lists), thereby reducing entry errors. ? Duplicate Data Verification: Utilising Excel's ‘Remove Duplicates’ and ‘Conditional Formatting’ functions to verify unique identifiers (e.g., admission numbers), ensuring no duplicate entries. ? Data Cleaning: Manually reviewing and verifying data completeness, consistency, and plausibility through Excel's sorting, filtering, and formula calculation capabilities. ? Privacy protection: All collected data undergoes anonymisation. Excel database files are password-protected and stored on institution-designated secure computers, accessible only to research team members. Regular database backups are performed. ? Data verification: A second person independently cross-checks consistency between original medical records and data entered into the Excel database, or conducts 100% verification of key indicators to ensure data accuracy.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-11 10:12:17